Drug Profile
CRX 100
Alternative Names: CRX-100Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator BioEclipse Therapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 08 Apr 2022 Safety, efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)